- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01916434
Farmed Fish Human Intervention Study (FISHDISH)
FIsh for a Sustainable Healthy Diet In Scottish Households Study
Consumption of fish can help to prevent cardiovascular disease. The precise way in which fish is beneficial is not fully understood. This is important to find out as fish consists of a complex mixture of fatty acids and micronutrients such as vitamin D and selenium that could individually, or collectively, be responsible for the beneficial effects.
Fish farming in Scotland is playing an increasingly important role in the provision of fish for human consumption. But issues with sustainability of raw materials are requiring fish farming to reformulate fish diets, which may affect the levels of beneficial omega-3 fatty acids and other components in fish.
In this study we will be comparing the long-term health effects of eating two portions a week of Scottish salmon raised on a traditional fish diet versus eating two portions a week of Scottish salmon raised on a more sustainable fish diet. In addition, we will be looking at differences in health outcomes when eating two portions a week of either Scottish salmon, compared with eating no fish at all.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aquaculture has the potential to take the pressure off wild fish stocks whilst meeting the dietary needs of the population for omega 3 fatty acids and other key nutrients such as vitamin D. The industry is working hard to improve sustainability - between 1995 and 2006 it has been estimated that the input to output ratios for salmon improved from 7.5 to 4.9 and trout from 6.0 to 3.4- but there is a need to do more. Reductions in fish stocks and catch quotas, in addition to sustainability considerations, mean that farmed fish may have to be raised on vegetable oils for example but this may reduce the omega 3 content and may affect the content of other nutrients. Fish are an important component of the diet and there is a need to understand the effect of pressures from sustainability on methods of production and the health giving properties of fish. We have now been commissioned by the Scottish Government's Rural and Environment Science and Analytical Services Division (RESAS) to do research on the health effects of Scottish farmed fish fed different feeding regimes in the Scottish population, and assess how differential effects in measured health outcomes could be related to fish composition.
Consumption of fish or omega-3- fatty acids from fish reduces coronary heart disease mortality, the leading cause of death in developed nations. The precise way in which fish provides benefit is not fully understood. This is important as fish and fish oils consist of a complex mixture of fatty acids and micronutrients that could individually, or collectively, be responsible for the beneficial effects. Aquaculture in Scotland is playing an increasingly important role in the provision of fish for human consumption, but issues with sustainability are requiring aquaculture to replace traditional fish oil and meal in formulated fish diets by oil from more sustainable sources, which may affect the levels of beneficial omega-3 fatty acids (EPA and DHA) and other components in fish. We will investigate the health effects of consuming two portions oily fish (Scottish farmed salmon) per week (current UK recommendation) using fish raised on different feeding regimes.
HYPOTHESIS
The health effects of consuming two portions oily fish (Scottish farmed salmon) per week (current UK recommendation) will be different for fish raised on different feeding regimes, primarily in terms of improving the omega-3 index.
OBJECTIVE
The main objective of this proposed study is to determine 1) whether the health benefits of consuming two portions of Scottish farmed salmon per week that have been fed a diet high in fish oil and fish meal significantly outweigh the health benefits of consuming two portions of Scottish farmed salmon per week that have been fed a diet with more sustainable levels of fish meal and fish oil, and 2) whether the difference in health benefits could justify the use of less sustainable dietary regimes for farmed fish.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Aberdeen, United Kingdom, AB21 9SB
- Rowett Institute of Nutrition and Health, Human Nutrition Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria: Healthy men and women aged 35-75 years BMI ranging from 18-35 kg/m2 Blood pressure below 160/90 mmHg; Total cholesterol < 8.00 mmol/L Total/HDL cholesterol < 6 mmol/L Fasting plasma glucose , 7 mmol/L Having a 10-20% risk for developing cardiovascular disease within the next 10 years based on the ASSIGN calculation (http://cvrisk.mvm.ed.ac.uk/index.htm) including the following factors: age, gender, number of cigarettes smoked per day, Scottish Index of Multiple Deprivation (SIMD)/postcode, systolic blood pressure, levels of total and HDL cholesterol and family history of cardiovascular disease, or having at least one additional risk factor such as being over 50 years old, BMI above 25 kg/m2, elevated triglyceride levels (> 1.7 mmol/L) or elevated glucose levels (> 5.6 mmol/L); platelet count > 1709/L haematocrit above 40 % for males and above 35 % for females haemoglobin above 130 g/L for males and above 115 g/L for females
Exclusion criteria Regularly taking aspirin or aspirin-containing drugs, or other anti-inflammatory drugs; Taking drugs or herbal medicines known to alter the haemostatic system in general; Taking any medicine known to affect lipid metabolism; Taking certain dietary supplements/multivitamin tablets; Diagnosis of diabetes, hypertension, renal, hepatic, haematological disease or coronary heart disease; Unsuitable veins for blood sampling; Inability to understand the participant information sheet; inability to speak, read and understand the English language.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: High Pufa Salmon Fillets
High EPA/DHA levels in feed and in salmon fillets (~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
|
High EPA/DHA levels in feed and in salmon fillets (~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
|
|
Experimental: Sustainable PUFA salmon
'Sustainable' levels of EPA/DHA in feed and in salmon fillets (~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption
|
'Sustainable' levels of EPA/DHA in feed and in salmon fillets (~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
|
|
Placebo Comparator: No salmon
The placebo group will continue to consume their habitual diet
|
The placebo group will continue to consume their habitual diet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the omega-3 index
Time Frame: At baseline and after 18 weeks salmon consumption
|
The Omega-3 index will be measured by GC-MS.
An optimal target level of the Omega-3 Index is 8%, and an undesirable level is less than 4%, with 4-8% being an intermediate-risk zone.
|
At baseline and after 18 weeks salmon consumption
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in cardiovascular risk markers
Time Frame: At baseline, after 9 weeks and after 18 weeks salmon consumption
|
This study will include the measurement of standard risk markers of cardiovascular disease at the start, middle and end of the intervention period, including lipoprotein metabolism (total cholesterol, LDL cholesterol, HDL cholesterol) and metabolic markers (glucose, insulin, triglycerides and non-esterified fatty acids to calculate HOMA-IR and revised QUICKI).
We will also measure 24-hrs ambulatory blood pressure.
|
At baseline, after 9 weeks and after 18 weeks salmon consumption
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bleeding time as measured by the platelet function analyzer (PFA-100)
Time Frame: At baseline and after 18 weeks salmon consumption
|
The PFA-100 simulates high shear platelet function in citrated blood within disposable test cartridges with membranes coated with either collagen/epinephrine (CEPI) or collagen/ADP (CADP).
The presence of these platelet activators and the high shear rates under the standardised conditions result in platelet adhesion, activation and aggregation resulting in formation of a platelet plug within the aperture.
Platelet function is thus measured as a function of the time it takes to occlude the aperture.
|
At baseline and after 18 weeks salmon consumption
|
|
Markers of coagulation and endothelial activation.
Time Frame: At baseline and after 18 weeks salmon consumption
|
Fibrinogen is a principle plasma glycoprotein involved in blood clotting.
Plasma clottable fibrinogen levels will be measured by Clauss method on a semi-automated coagulometer using Fibrinogen assay thrombin reagent from Helena Biosciences, England.
Von Willebrand factor (vWF) is another plasma glycoprotein involved in coagulation and an established marker of endothelial activation or damage.
Plasma levels of vWF will be measured by an in-house ELISA using polyclonal antibodies and horseradish peroxidase-conjugated antibody from DAKO Ltd, Denmark.
P-selectin is a cell adhesion molecule present in platelet granules and (to a lesser extent) in endothelial cells.
sP-selectin levels in fasted blood plasma will be measured in duplicate by ELISA (Bender Med Systems)
|
At baseline and after 18 weeks salmon consumption
|
|
Markers of inflammation.
Time Frame: At baseline and after 18 weeks salmon consumption
|
CRP is an acute phase protein synthesised by the liver in response to inflammatory stimuli, especially the cytokine IL-6.
hsCRP will be measured in duplicate by an ultra sensitive, double antibody ELISA.
Soluble -ICAM is a marker of endothelial activation and inflammation, during which it promotes leucocyte adherence to the endothelium.
Plasma soluble I-CAM levels will be measured in duplicate by ELISA (Bender Med Systems).
Epoxyeicosatrieonic acids (EETs) are anti-inflammatory and cardioprotective compounds.
Their availability and metabolism are regulated by the enzyme soluble epoxide hydrolase (sEH), which in turn is affected by EPA.
EETs will be measured in platelets using LC-MS/MS.
|
At baseline and after 18 weeks salmon consumption
|
|
Markers of oxidative stress.
Time Frame: At baseline and after 18 weeks salmon consumption
|
F2-isoprostanes are currently considered as reference biomarkers for lipid peroxidation and will be measured by LC-MS/MS.
|
At baseline and after 18 weeks salmon consumption
|
|
Markers of micronutrient availability
Time Frame: At baseline and after 18 weeks salmon consumption
|
Selenium in incorporated into proteins within the body, many of which are antioxidants that protect the body against oxidative damage.
Selenium is transported across the body within the protein, selenoprotein P (SEPP-1).
Selenium status will be measured by assaying plasma selenium levels (by ICP-MS) and by quantification of plasma SEPP-1 levels (by an in-house ELISA).
Iodine status will be measured by assaying urinary iodine levels (by ICP-MS) and vitamin D status will be assessed by measuring plasma 25-hydroxy vitamin D (using HPLC and LC/MS/MS).
|
At baseline and after 18 weeks salmon consumption
|
|
Markers of gut health
Time Frame: At baseline and after 18 weeks salmon consumption
|
Faecal samples will be collected for the isolation of faecal waters to measure NFkb activation, micronutrient levels, genetic health and antioxidant potential (ORAC, TRAC etc), as well as the measurement of stool content and stool pH.
|
At baseline and after 18 weeks salmon consumption
|
|
Markers of genetic health
Time Frame: At baseline and after 18 weeks salmon consumption
|
The buffy coat from spun whole blood samples will be collected to measure patterns of DNA methylation contributing to epigenetic inheritance.
|
At baseline and after 18 weeks salmon consumption
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Baukje De Roos, Msc, PhD, University of Aberdeen Rowett Institute of Nutrition and Health
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingCardiovascular Disease (CVD) | Gender Incongruence | Cardiovascular (CV) Risk | Cardiovascular Health Status | Cardiovascular Disease Prevention | Cardiovascular Disease Acute | Cardiovascular Disease Risk FactorItaly
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
University College DublinBeacon Hospital, IrelandRecruitingCoronary Artery Disease (CAD) | Cardiovascular Diseases (CVD) | Cardiovascular Disease Prevention | Cardiovascular Disease Risk FactorIreland
-
Fu Jen Catholic UniversityRecruitingCardiovascular Disease | Cardiovascular SurgeryTaiwan
-
Istituti Clinici Scientifici Maugeri SpAA.R.C.A Associazioni Regionali Cardiologi AmbulatorialiRecruiting
-
AmgenRecruitingCardiovascular DiseaseItaly, Germany, United States, China, Japan, Spain, Denmark, Australia, France, Canada, Netherlands
-
University of ReadingBiotechnology and Biological Sciences Research Council; Royal Berkshire NHS...Not yet recruiting
-
Nanjing Medical UniversityRecruiting
-
Centre Hospitalier Universitaire de la RéunionRecruitingCardiovascular DiseaseFrance
Clinical Trials on High PUFA Salmon Fillets
-
Mead Johnson NutritionNorth Shore Research InstitueCompleted
-
Fundacion para la Formacion e Investigacion Sanitarias...Recruiting
-
Poznan University of Life SciencesUnknown
-
National Institute of Nutrition and Seafood Research...Haukeland University HospitalCompleted
-
S.LAB (SOLOWAYS)Center for New Medical Technologies, Novosibirsk, RussiaCompleted
-
Fundacion GESICAUnknown
-
Imperial College LondonTerminatedAtherosclerosisUnited Kingdom